Login to Your Account



Behcet's Uveitis up First

XOMA Inks $505M Servier Pact for IL-1 Inhibitor XOMA 052

By Jennifer Boggs


Wednesday, January 5, 2011
XOMA Ltd. is picking up about $35 million up front in a creatively structured ex-U.S. deal with French firm Les Laboratoires Servier, which gives the Berkeley, Calif.-based biotech the chance to retain long-term upside on interleukin-1 inhibitor XOMA 052, a drug that has generated significant buzz in early stage diabetes trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription